Taysha Gene Therapies Return on Tangible Equity 2020-2026 | TSHA
Current and historical return on tangible equity values for Taysha Gene Therapies (TSHA) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Taysha Gene Therapies Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2026-03-31 | $-0.13B | $0.23B | -56.09% |
| 2025-12-31 | $-0.11B | $0.19B | -57.14% |
| 2025-09-30 | $-0.10B | $0.15B | -67.90% |
| 2025-06-30 | $-0.09B | $0.12B | -80.86% |
| 2025-03-31 | $-0.09B | $0.08B | -108.31% |
| 2024-12-31 | $-0.09B | $0.08B | -111.11% |
| 2024-09-30 | $-0.02B | $0.08B | -28.13% |
| 2024-06-30 | $-0.11B | $0.05B | -241.27% |
| 2024-03-31 | $-0.12B | $0.01B | -1097.67% |
| 2023-12-31 | $-0.11B | $-0.01B | 1723.08% |
| 2023-09-30 | $-0.22B | $-0.03B | 860.00% |
| 2023-06-30 | $-0.13B | $-0.01B | 1250.00% |
| 2023-03-31 | $-0.13B | $0.01B | -1786.67% |
| 2022-12-31 | $-0.17B | $0.02B | -691.67% |
| 2022-09-30 | $-0.16B | $0.05B | -338.95% |
| 2022-06-30 | $-0.19B | $0.08B | -231.97% |
| 2022-03-31 | $-0.19B | $0.12B | -162.71% |
| 2021-12-31 | $-0.17B | $0.16B | -108.07% |
| 2021-09-30 | $-0.14B | $0.20B | -71.00% |
| 2021-06-30 | $-0.11B | $0.23B | -45.69% |
| 2021-03-31 | $-0.09B | $0.19B | -46.36% |
| 2020-12-31 | $-0.06B | $0.13B | -45.47% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.290B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |